Press Releases

SOUTH PLAINFIELD, N.J. , Jan. 3, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the company will present a corporate update at the upcoming 35 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 7:30 am PT .

SOUTH PLAINFIELD, N.J. , Dec. 16, 2016 /PRNewswire/ --  PTC Therapeutics, Inc.  ( NASDAQ : PTCT) today announced that on December 14, 2016 it approved non-statutory stock options to purchase an aggregate of 5,600 shares of its common stock to two new employees.

- Award recognizes scientific innovation of first approved drug for underlying cause of nonsense mutation Duchenne muscular dystrophy -

SOUTH PLAINFIELD, N.J. , Nov. 18, 2016 /PRNewswire/ --  PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that on November 17, 2016 it approved non-statutory stock options to purchase an aggregate of 33,600 shares of its common stock to eight new employees.

--PTC to conduct a post-authorization clinical trial --

- Record quarter with Translarna™ net sales of $22M; 125% year-over-year growth -
- YTD Translarna net sales of $56M; on track for $65M to $85M full year guidance -
- Successful pricing and reimbursement negotiations concluded in Italy and Romania -
- CHMP opinion regarding Translarna's EMA marketing renewal expected by year-end -
- SMA program advancing with Phase 2 SUNFISH study initiated in Type 2/3 patients -

- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -
- FIREFISH study in Type I SMA patients expected to begin in the coming months -

SOUTH PLAINFIELD, N.J. , Oct. 19, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company's business and outlook on Wednesday, November 2,

SOUTH PLAINFIELD, N.J. , Oct. 17, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today provided a regulatory update on Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). U.S. regulatory update PTC Therapeutics announced today that at the

SOUTH PLAINFIELD, N.J. , Oct. 6, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. ( NASDAQ : PTCT) today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory nonsense mutation Duchenne muscular dystrophy patients (nmDMD).